Neurotrophic activities and therapeutic experience with a brain derived peptide preparation

Journal of Neural Transmission, Supplement

Volumn , Issue 53, 1998, Pages 289-298

  Windisch, M ^a   Gschanes, A ^a   Hutter Paier, B ^a  

^a Research Initiative Ebewe   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CEREBROLYSIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; AMINO ACID; NOOTROPIC AGENT;

ARTICLE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; NERVE REGENERATION; PRIORITY JOURNAL; TREATMENT OUTCOME; AGED; ALZHEIMER DISEASE; ANIMAL; CLINICAL TRIAL; HUMAN; PSYCHOLOGICAL ASPECT; REVIEW;

AGED; ALZHEIMER DISEASE; AMINO ACIDS; ANIMALS; CLINICAL TRIALS; HUMANS; NOOTROPIC AGENTS;

EID: 0031596269     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6467-9_25     Document Type: Article

References (40)

1. Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Ioku M, Hashimoto S (1992) Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 7: 213-221
2. Albrecht E, Hingel S, Crailsheim K, Windisch M (1993) The effects of cerebrolysin on survival and sprouting of neurons from cerebral hemispheres and from the brainstem of chick embryos in vitro. Adv Biosci 87: 341-442
3. Anand R, Gharabawi G (1996) Clinical development of ExelonTM (ENA-713): the Adena programme. J Drug Dev Clin Pract 8: 117-122
4. Barde YA (1989) Trophic factors and neuronal survival. Neuron 2: 1525-1534
5. Boado RJ (1995) Brain-derived peptides regulate the steady state levels and increase stability of the blood-brain barrier GLUT1 glucose transporter mRNA. Neurosci Lett 197: 179-182
6. Boado RJ (1996) Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Neurosci Lett 220: 53-56
7. Boado RJ, Wu D, Pardridge WM, Windisch M (1997) In vivo administration of brain-derived peptides increases the transport of glucose from blood to brain. J Neurol Sci 150: 77
8. Boissiere F, Hunot S, Faucheeux B, Mouatt-Prigent A, Agid Y, Hirsch EC (1997) Trk neurotrophin receptors in cholinergic neurons of patients with Alzheimer's disease. Dementia 8: 1-8
9. Cummings J, Bieber F, Mas J, Orazem J, Gulanski B (1997) Metrifonate in Alzheimer's disease: results of a dose-finding study. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (eds) Alzheimer's disease: biology, diagnosis and therapeutics. Wiley, New York, pp 659-669
10. Francis-Turner L, Valouskova V (1996a) Nerve growth factor and nootropic drug cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci Lett 202: 1-4
11. Francis-Turner L, Valouskova V, Mokry J (1996b) Long-term effect of NGF, b-FGF and cerebrolysin on the spatial memory after fimbria-fornix lesion in rats. J Neural Transm 47: 277
12. Gavrilova SI, Selezneva ND, Kolykhalov IV, Roschina IF, Jarikov GA (1997) Efficacy of cerebrolysin in Alzheimer's disease. Eur Neuropsychopharmacol 7: 4
13. Gschanes A, Windisch M (1996) The influence of cerebrolysin and EO21 on spatial navigation of young rats. J Neural Transm 47: 278
14. Gschanes A, Windisch M (1997) The influence of brain-derived peptides on spatial navigation of young and adult rats. Soc Neurosci Abstr 23: 1842
15. Hampson DR, Windisch M, Baskys A (1997) Increased binding of BDNF to trkB induced by the antidementia drug cerebrolysin. Soc Neurosci Abstr 23: 1896
16. Hefti F (1994) Growth factors and neurodegeneration. In: Calne D (ed) Neuro-degenerative diseases. Saunders, Philadelphia, pp 177-194
17. Hutter-Paier B, Eggenreich U, Windisch M (1996) Effects of two protein-free peptide derivatives on passive avoidance behaviour of 24-month-old rats. Arzneimittelforschung/Drug Res 46/1: 237-241
18. Hutter-Paier B, Grygar E, Windisch M (1996a) Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative cerebrolysin. J Neural Transm 47: 267-273
19. Hutter-Paier B, Frühwirth M, Windisch M (1996b) Ischemia induced loss of map2 is prevented by cerebrolysin and THA. Mol Biol Cell 7: 1278
20. Kofler B, Erhart C, Erhart P, Harrer G (1990) A multidimensional approach in testing nootropic drug effects (cerebrolysin) -in press. Arch Geront Geriatr 10: 129-140
21. Lapchak PA, Araujo DM, Hefti F (1993) Regulation of hippocampal muscarinic receptor function by chronic nerve growth factor treatment in adult rats with fimbrial transections. Neuroscience 53/2: 379-394
22. Lapchak PA, Hefti F (1991) Emerging pharmacology of nerve growth factor. Prog Neuro-psychopharmacol Biol Psychiatry 15: 851-860
23. Lin JH, Hu GY, Tang XC (1997) Comparison between huperzine A, tacrine, and E2020 on cholinergic transmission at mouse neuromuscular junction in vitro. Chung Kuo Yao Li Hsueh Pao 18/1: 6-10
24. Lindner G (1975) Effects of brain extract and hydrolysate on nerve tissue in vitro. Z Mikrosk Anat Forsch 89: 815-823
25. Lindsay RM (1994) Neurotrophic growth factors and neurodegenerative diseases: therapeutic potential of the neurotrophins and ciliary neurotrophic factor. Neurobiol Aging 15/2: 249-251
26. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD (1995) Neuro-degeneration in the central nervous system of apoE-deficient mice. Exp Neurol 136: 107-122
27. Masliah E, Armasola F, Veinbergs I, Mallory M, Samuel W (1997) Neurotrophic and neuroprotective effects of cerebrolysin in experimental models of neuro-degeneration. Internal Research Report
28. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H (1996) Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7: 1-4
29. Olson L, Nordberg A, vonHolst H, et al (1992) Nerve growth factor affects 11C-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient. J Neural Transm 4: 79-95
30. Rainer M, Brunnbauer M, Dunky A, Ender F, Goldsteiner H, Holl O, Kotlan P, Paulitsch G, Reiner C, Stössl J, Zachhuber C, Mössler H (1997) Therapeutic results with cerebrolysin in the treatment of dementia. Wien Med Wochenschr 147: 426-431
31. Rüther E, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27/1: 32-40
32. Satou T, Imano M, Akai F, Hashimoto S, Itoh T, Fujimoto M (1993) Morphological observation of effects of cerebrolysin on cultured neural cells. Adv Biosci 87: 195-196
33. Satou T, Itoh T, Fujimoto M, Hashimoto S (1994) Neurotrophic-like effects of FPF-1070 on cultured neurons from chick embryonic dorsal root ganglia. Jpn Pharmacol Ther 22/4: 205-212
34. Seiger AKE, Nordberg A, von Holst H, Bäckmann L, Ebendal T, Alafuzoff I, Amberla K (1993) Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res 57: 255-261
35. Shimazu S, Iwamoto N, Itoh T, Akasako A, Seki H, Jujimoto M (1991) Neurotrophic activity of cerebrolysin. Second International Springfield Symposium on Advantage in Alzheimer Therapy, Springfield, USA, p 51
36. Siegfried K (1995) The efficacy of cholinergic drugs in patients with Alzheimer's disease - focus on the aminoacridines. Humanpsychopharmacology 10: 89-96
37. Sofroniew MV, Cooper JD (1993) Neurotrophic mechanisms and neuronal degeneration. Neurosciences 5: 285-249
38. Suchanek-Fröhlich H, Wunderlich E (1987) Randomized, plazebo-controlled, double-blind study with an amino-acid-peptid extract. Prakt Arzt 1: 1027-1034
39. Wenzel JM, Grosse G, Lindner G, Kirsche W, Matthies H (1977) Die Wirkung von Aminosäuren auf die vitro-Differenzierung von Hippocampusneuronen - morphometrische und elektronenmikroskopische Untersuchung über Ribosomen, Protheinsynthese und Synaptogenese. J Hirnforsch 18: 357-371
40. Yuen EC, Mobley WC (1996) Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol 40/3: 346-354